Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice

• Published in: Nutrition & diabetes 2023-11, Vol.13 (1), p.19-19, Article 19
• Main Authors: Lee, Jungu, Jeon, Suyeon, Lee, Mijeong, Yoon, Michung
• Format: Article
• Language: English
• Subjects: 38/1; 38/77; 631/443/319/1642/2815; 631/443/319/1642/393; 64/60; Adipocytes; Animals; Body fat; Clinical Nutrition; Diabetes; Diet; Epidemiology; Female; Fenofibrate - metabolism; Fenofibrate - pharmacology; Fenofibrate - therapeutic use; Glucose; Humans; Hyperglycemia; Hyperlipidemias; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Insulin Resistance; Internal Medicine; Liver - metabolism; Medical research; Medicine; Medicine & Public Health; Metabolic Diseases; Metabolic disorders; Mice; Mice, Inbred C57BL; Mice, Obese; Nutrition research; Obesity; Obesity - drug therapy; Obesity - metabolism; Pancreas; Polymerase chain reaction; Statistical analysis; Tumor Necrosis Factor-alpha - metabolism; Tumor necrosis factor-TNF
• ISSN: 2044-4052; 2044-4052
• DOI: 10.1038/s41387-023-00249-z

Background Fenofibrate is a hypolipidemic peroxisome proliferator-activated receptor α (PPARα) agonist used clinically to reduce hypercholesterolemia and hypertriglyceridemia. Objective We investigated the effects of fenofibrate on insulin resistance and tissue inflammation in a high-fat diet (HFD)-fed ovariectomized (OVX) C57BL/6J mice, a mouse model of obese postmenopausal women. Methods Female OVX mice were randomly divided into 3 groups and received a low-fat diet, an HFD, or an HFD supplemented with 0.05% (w/w) fenofibrate for 9 weeks. Parameters of insulin resistance and tissue inflammation were measured using blood analysis, histological analysis, immunohistochemistry, and quantitative real-time polymerase chain reaction. Results When fenofibrate was administered to HFD-fed OVX mice for 9 weeks, we observed reductions in body weight gain, adipose tissue mass, and the size of visceral adipocytes without the change of food intake. Fenofibrate improved mild hyperglycemia, severe hyperinsulinemia, and glucose tolerance in these mice. It also reduced pancreatic islet size and insulin-positive β-cell area to levels similar to those in OVX mice fed a low-fat diet. Concomitantly, administration of fenofibrate not only suppressed pancreatic lipid accumulation but also decreased CD68-positive macrophages in both the pancreas and visceral adipose tissue. Treatment with fenofibrate reduced tumor necrosis factor α (TNFα) mRNA levels in adipose tissue and lowered serum TNFα levels. Conclusion These results suggest that fenofibrate treatment attenuates insulin resistance in part by reducing tissue inflammation and TNFα expression in HFD-fed OVX mice.